The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
T2T Validation - Endolysosomal Targets, 2025Exploring TMEM175 as a Key Target in the Pathogenesis of Parkinson's Disease
Study Rationale: Genetic variants in TMEM175 are amongst the top 5 strongest genetic risk variants in Parkinson’s disease (PD), with one variant increasing risk for the disease, and one variant...
-
Research Grant, 2025Alpha-synuclein PET Imaging in Patients
Study Rationale: We developed [11C]SY08 for alpha-synuclein PET imaging. Our early findings in people showed increased brainstem binding and a trend towards increased cortical binding in Parkinson’s...
-
Spring 2025 RFP: Accelerating Biological Understanding and Therapeutic Translation for PD- Biology, 2025The Role of the Transcriptome in PD: A Novel Approach to PD Therapeutics
Study Rationale: Families, caregivers, and individuals living with Parkinson’s disease are in need of new biomarkers and effective therapies. To date, most of the studies have focused on DNA and...
-
Summer 2025 RFP: Accelerating Biological Understanding and Translational Approaches for PD Program - Biology, 2025RNAi Therapeutics Targeting Stearoyl-CoA-Desaturase as a Disease-modifying Treatment for Parkinson’s Disease
Study Rationale: Previous research has found that a type of fat molecules, called unsaturated fatty acids, are important regulators of toxicity in brain cells caused by the protein alpha-synuclein – a...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025Development of CNS-Specific mTOR Inhibition for Enhanced Autophagy and Alpha-synuclein Clearance in Parkinson’s Disease
Study Rationale: A major problem in Parkinson’s disease (PD) is the buildup of a protein called alpha-synuclein, which damages brain cells. One way to help clear this toxic protein is by activating a...
-
Spring 2025 RFP: Accelerating Biological Understanding and Therapeutic Translation for PD- Biology, 2025Determining PINK1 and PRKN Enzyme Activities In Vivo.
Study Rationale: In Parkinson’s disease, loss of nigral dopaminergic neurons leads to motor symptoms. PINK1 and PRKN are both proteins involved in mitochondrial quality control, which when carrying...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.